- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
VRIO Analysis of Abiomed and the AbioCor Clinical Trials B
Posted by Zachary Edwards on Mar-22-2018
The VRIO Analysis of Abiomed and the AbioCor Clinical Trials B will look at each of its internal resources one by one to assess whether these provide sustained competitive advantage. The Abiomed and the AbioCor Clinical Trials B VRIO Analysis also mentions at each stage whether these resources could be improved to provide a greater competitive advantage. Lastly, the resources analysed are summarised as to whether they offer sustained competitive advantage, has an unused competitive advantage, temporary competitive advantage, competitive parity or competitive disadvantage.
Valuable
- The Abiomed and the AbioCor Clinical Trials B VRIO Analysis shows that the financial resources of Abiomed and the AbioCor Clinical Trials B are highly valuable as these help in investing into external opportunities that arise. These also help Abiomed and the AbioCor Clinical Trials B in combating external threats.
- According to the VRIO Analysis of Abiomed and the AbioCor Clinical Trials B, its local food products are a valuable resource as these are highly differentiated. This makes the perceived value for these by customers high. These are also valued more than the competition by customers due to the differentiation in these products.
- The Abiomed and the AbioCor Clinical Trials B VRIO Analysis shows that Abiomed and the AbioCor Clinical Trials B's employees are a valuable resource to the firm. A significant portion of the workforce is highly trained, and this leads to more productive output for the organisation. The employees are also loyal, and retention levels for the organisation are high. All of this translates into greater value for the end consumers of Abiomed and the AbioCor Clinical Trials B's products.
- According to the VRIO Analysis of Abiomed and the AbioCor Clinical Trials B, its patents are a valuable resource as these allow the firm to sell its products without competitive interference. This results in greater revenue for Abiomed and the AbioCor Clinical Trials B. These patents also provide Abiomed and the AbioCor Clinical Trials B with licensing revenue when it licenses these patents out to other manufacturers.
- The Abiomed and the AbioCor Clinical Trials B VRIO Analysis shows that Abiomed and the AbioCor Clinical Trials B’s distribution network is a valuable resource. This helps it in reaching out to more and more customers. This ensures greater revenues for Abiomed and the AbioCor Clinical Trials B. It also ensures that promotion activities translate into sales as the products are easily available.
- According to the VRIO Analysis of Abiomed and the AbioCor Clinical Trials B, its cost structure is not a valuable resource. This is because the methods of production lead to greater costs than that of competition, which affects the overall profits of the firm. Therefore, its cost structure is a competitive disadvantage that needs to be worked on.
- The Abiomed and the AbioCor Clinical Trials B VRIO Analysis shows that the research and development at Abiomed and the AbioCor Clinical Trials B is not a valuable resource. This is because research and development are costing more than the benefits it provides in the form of innovation. There have been very few innovative features and breakthrough products in the past few years. Therefore, research and development are a competitive disadvantage for Abiomed and the AbioCor Clinical Trials B. It is recommended that the research and development teams are improved, and costs are cut for these.
Rare
- The financial resources of Abiomed and the AbioCor Clinical Trials B are found to be rare according to the VRIO Analysis of Abiomed and the AbioCor Clinical Trials B. Strong financial resources are only possessed by a few companies in the industry.
- The local food products are found to be not rare as identified by Abiomed and the AbioCor Clinical Trials B VRIO Analysis. These are easily provided in the market by other competitors. This means that competitors can use these resources in the same way as Abiomed and the AbioCor Clinical Trials B and inhibit competitive advantage. This means that the local food products result in competitive parity for Abiomed and the AbioCor Clinical Trials B. As this resource is valuable, Abiomed and the AbioCor Clinical Trials B can still make use of this resource.
- The employees of Abiomed and the AbioCor Clinical Trials B are a rare resource as identified by the VRIO Analysis of Abiomed and the AbioCor Clinical Trials B. These employees are highly trained and skilled, which is not the case with employees in other firms. The better compensation and work environment ensure that these employees do not leave for other firms.
- The patents of Abiomed and the AbioCor Clinical Trials B are a rare resource as identified by the Abiomed and the AbioCor Clinical Trials B VRIO Analysis. These patents are not easily available and are not possessed by competitors. This allows Abiomed and the AbioCor Clinical Trials B to use them without interference from the competition.
- The distribution network of Abiomed and the AbioCor Clinical Trials B is a rare resource as identified by the VRIO Analysis of Abiomed and the AbioCor Clinical Trials B. This is because competitors would require a lot of investment and time to come up with a better distribution network than that of Abiomed and the AbioCor Clinical Trials B. These are also possessed by very few firms in the industry.
Imitable
- The financial resources of Abiomed and the AbioCor Clinical Trials B are costly to imitate as identified by the Abiomed and the AbioCor Clinical Trials B VRIO Analysis. These resources have been acquired by the company through prolonged profits over the years. New entrants and competitors would require similar profits for a long period of time to accumulate these amounts of financial resources.
- The local food products are not that costly to imitate as identified by the VRIO Analysis of Abiomed and the AbioCor Clinical Trials B. These can be acquired by competitors as well if they invest a significant amount in research and development. These also do not require years long experience. Therefore, the local food products by Abiomed and the AbioCor Clinical Trials B provide it with a temporary competitive advantage that competitors can too acquire in the long run.
- The employees of Abiomed and the AbioCor Clinical Trials B are also not costly to imitate as identified by the Abiomed and the AbioCor Clinical Trials B VRIO Analysis. This is because other firms can also train their employees to improve their skills. These companies can also hire employees from Abiomed and the AbioCor Clinical Trials B by offering better compensation packages, work environment, benefits, growth opportunities etc. This makes the employees of Abiomed and the AbioCor Clinical Trials B a resource that provides a temporary competitive advantage. Competition can acquire these in the future.
- The patents of Abiomed and the AbioCor Clinical Trials B are very difficult to imitate as identified by the VRIO Analysis of Abiomed and the AbioCor Clinical Trials B. This is because it is not legally allowed to imitate a patented product. Similar resources to be developed and getting a patent for them is also a costly process.
- The distribution network of Abiomed and the AbioCor Clinical Trials B is also very costly to imitate by competition as identified by the Abiomed and the AbioCor Clinical Trials B VRIO Analysis. This has been developed over the years gradually by Abiomed and the AbioCor Clinical Trials B. Competitors would have to invest a significant amount if they are to imitate a similar distribution system.
Organisation
- The financial resources of Abiomed and the AbioCor Clinical Trials B are organised to capture value as identified by the VRIO Analysis of Abiomed and the AbioCor Clinical Trials B. These resources are used strategically to invest in the right places; making use of opportunities and combatting threats. Therefore, these resources prove to be a source of sustained competitive advantage for Abiomed and the AbioCor Clinical Trials B.
- The Patents of Abiomed and the AbioCor Clinical Trials B are not well organised as identified by the Abiomed and the AbioCor Clinical Trials B VRIO Analysis. This means that the organisation is not using these patents to their full potential. An unused competitive advantage exists that can be changed into a sustainable competitive advantage if Abiomed and the AbioCor Clinical Trials B starts selling patented products before the patents expire.
- The distribution network of Abiomed and the AbioCor Clinical Trials B is organised as identified by the VRIO Analysis of Abiomed and the AbioCor Clinical Trials B. Abiomed and the AbioCor Clinical Trials B uses this network to reach out to its customers by ensuring that products are available on all of its outlets. Therefore, these resources prove to be a source of sustained competitive advantage for Abiomed and the AbioCor Clinical Trials B.
From the VRIO Analysis of Abiomed and the AbioCor Clinical Trials B, it was identified that the financial resources and distribution network provide a sustained competitive advantage. The patents are a source of unused competitive advantage. There exists a temporary competitive advantage for employees. There exists a competitive parity for local food products. Lastly, the cost structure of Abiomed and the AbioCor Clinical Trials B is a competitive disadvantage. Research and Development is also a competitive disadvantage.
Warning! This article is only an example and cannot be used for research or reference purposes. If you need help with something similar, please submit your details here.
Pooja Dembda
5.0
Thank you for making a Cartesian graph with Pictogram. Yeah, I wanted this. I received the assignment yesterday and checked it many times and really love the way in which you did it.
Ethan Breyden
5.0
Speedy turnaround and I like this service due to its great performance. Thanks!
Gema Scott
5.0
Always on-time System of a professional writer The cooperative customer support. Thank you so much!
Samuel Mark
5.0
I recommend this service to every student who needs a comprehensive and plagiarism free assignment. I’m thoroughly delighted. Thank you so much!
Next Articles
- SKOLAR, M.D.: Is There A Business For Web Based Information For Doctors? Vrio Analysis
- Merck: Global Health And Access To Medicines Vrio Analysis
- Genzyme: The Renvela Launch Decision Vrio Analysis
- Changing Corporate Identity: The Case Of A Regional Hospital Vrio Analysis
- Population Services International: The Social Marketing Project In Bangladesh (Abridged) Vrio Analysis
- Planned Parenthood Federation Of America (A) Vrio Analysis
- Pearle Vision: Clearly Different? Vrio Analysis
- 3M Chile: Health Care Products (A) Vrio Analysis
- CFW Clinics In Kenya: To Profit Or Not For Profit Vrio Analysis
- Beth Israel Hospital, Boston Vrio Analysis
Previous Articles
- Kendall Vetmat Vrio Analysis
- Access Health CT: Marketing Affordable Care (A) Vrio Analysis
- Babeeze In Arms Doula Centre Vrio Analysis
- Population Services International: The Social Marketing Project In Bangladesh, Chinese Version Vrio Analysis
- EPhysician Vrio Analysis
- Med Mart: Transitioning The Business Model (B) Vrio Analysis
- PacifiCare's African American Health Solutions (AAHS) Vrio Analysis
- Cardinal Health (A): The Medicine Shoppe Acquisition Vrio Analysis
- Uptake Of Malaria Rapid Diagnostic Tests Vrio Analysis
- Canadian Blood Services Vrio Analysis
Be a great writer or hire a greater one!
Academic writing has no room for errors and mistakes. If you have BIG dreams to score BIG, think out of the box and hire Case48 with BIG enough reputation.
Our Guarantees
Interesting Fact
Most recent surveys suggest that around 76 % students try professional academic writing services at least once in their lifetime!